A seroprevalence study of poliovirus antibody against a collection of recombinant and non-recombinant poliovirus vaccine strains in the population of southern Greece

Clinical Microbiology and Infection

Volumn 16, Issue 11, 2010, Pages 1672-1675

  Pliaka, V ^a   Ruether, I G A ^a   Kyriakopoulou, Z ^a   Kioussi, P ^a   Plakokefalos, E ^a   Megalou, M ^a   Pratti, A ^a   Levidiotou Stefanou, S ^b   Markoulatos, P ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Greece; Immunity; OPV derivatives; Polioviruses

Indexed keywords

ORAL POLIOMYELITIS VACCINE; RECOMBINANT VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; CHILD; GREECE; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SEROPREVALENCE; VACCINATION; VIRUS NEUTRALIZATION;

HUMAN POLIOVIRUS 3; POLIOVIRUS;

EID: 77958592540     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03188.x     Document Type: Article

References (21)

1. Kew OM, Sutter RW, De Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived poliovirus and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59: 587-635.
2. World Health Organization. Manual for the virological investigation of poliomyelitis. WHO/EPI/GEN/04. Geneva: WHO, 2004.
3. Centers for Disease Control. Progress toward interruption of wild poliovirus transmission-worldwide, January 2007-April 2008. MMWR 2008; 57: 489-494.
4. Kew O, Morris-Glasgow V, Landaverde M et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296: 356-359.
5. Shimizu H, Thorley B, Paladin FJ et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol 2004; 78: 13512-13521.
6. Rousset D, Rakato-Andrianarivelo M, Razafindratsimandresy R et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis 2003; 9: 885-887.
7. Centers for Disease Control and Prevention. Acute flaccid paralysis surveillance for expansion to other diseases, 2003-2004. MMWR 2004; 53: 1113-1116.
8. Heymann DL, Sutter RW, Aylward RB. A vision of a world without polio: the OPV cessation strategy. Biologicals 2006; 34: 75-79.
9. Frantzidou-Adamopoulou F. Poliomyelitis cases in Northern Greece 1976-1990. Eur J Epidemiol 1992; 8: 112-113.
10. World Health Organization. Manual for the virological investigation of polio. WHO/EPI/GEN 97.01. Geneva: WHO, 1997.
11. Gracia Ahufinger I, Tamames Gomez S, Eiros Bouza JM et al. HIV seroprevalence in the population treated in a hospital emergency department: analysis by pooled batches of serum. Rev Clin Esp 2009; 209: 73-77.
12. Dedepsidis E, Kyriakopoulou Z, Pliaka V et al. Retrospective characterization of a vaccine-derived poliovirus type 1 isolate from sewage in Greece. Appl Environ Microbiol 2007; 73: 6697-6704.
13. Karakasiliotis I, Paximadi E, Markoulatos P. Evolution of a rare vaccine-derived multirecombinant poliovirus. J Gen Virol 2005; 86: 3137-3142.
14. Paximadi E, Karakasiliotis I, Mamuris Z, Stathopoulos C, Krikelis V, Markoulatos P. Genomic analysis of recombinant sabin clinical isolates. Virus Genes 2006; 32: 203-210.
15. Karakasiliotis I, Markoulatos P, Katsorchis T. Site analysis of recombinant and mutant poliovirus isolates of Sabin origin from patients and from vaccinees. Mol Cell Probes 2004; 18: 103-109.
16. Paximadi E, Karakasiliotis I, Bolanaki E, Krikelis A, Markoulatos P. Vaccine derived bi- and multi-recombinant Sabin strains. Virus Genes 2007; 35: 541-548.
17. Dedepsidis E, Pliaka V, Kyriakopoulou Z et al. Complete genomic characterization of an intertypic Sabin3/Sabin2 capsid recombinant. FEMS Immunol Med Microbiol 2008; 52: 343-351.
18. Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin Microbiol Infect 2005; 11: 68-71.
19. Mastroeni I, Patii AM, Fabrizi A et al. Immunity status against poliomyelitis in persons 13-14 years old living in Rome. Vaccine 1997; 15: 745-750.
20. White PM, Green J. Prevalence of antibody to polioviruses in England and Wales 1984-6. BMJ 1986; 293: 1153-1155.
21. Katz Samuel L. Polio-new challenges in 2006. J Clin Virol 2006; 36: 163-165.